Literature DB >> 28270948

Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.

Necati Muşlu1, Bahadır Ercan2, Serin Akbayır3, Şenay Balcı1, H Didem Ovla4, Murat Bozlu5.   

Abstract

OBJECTIVE: Prostate specific antigen (PSA) with digital rectal examination is used for diagnosis of prostate cancer (PCa), where definite diagnosis can only be made by prostate biopsy. Recently neutrophil gelatinase-associated lipocalin (NGAL), a lipocalin family member glycoprotein, come into prominence as a cancer biomarker. This study is aimed to test serum NGAL as a diagnostic biomarker for PCa and discriminate PCa from benign prostatic hyperplasia (BPH).
MATERIAL AND METHODS: In this prospective study, 90 patients who underwent transrectal ultrasound-guided 12-core prostate biopsy between May 2015 and September 2015, were evaluated. Histopathologically diagnosed 45 PCa and 45 BPH patients were enrolled in this study. Serum NGAL and PSA levels of all participants were measured, then these data were evaluated by statistical programs.
RESULTS: When sensitivity fixed to 80% specificity of NGAL was better than PSA (49%, 31% respectively). Receiver operating characteristic (ROC) curve analysis showed that NGAL alone or its combined use with PSA have better area under curve (AUC) results than PSA alone (0.662, 0.693, and 0.623 respectively).
CONCLUSION: In conclusion NGAL gave promising results such as increased sensitivity and a better AUC values in order to distinguish PCa from BPH. NGAL showed a potential to be a non-invasive biomarker which may decrease the number of unnecessary biopsies.

Entities:  

Keywords:  Biomarker; NGAL; PSA; cancer; hypertrophy; prostate

Year:  2017        PMID: 28270948      PMCID: PMC5330265          DOI: 10.5152/tud.2016.08941

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  31 in total

Review 1.  [KIM-1 and NGAL as potential biomarkers for the diagnosis and cancer progression].

Authors:  Zofia Marchewka; Aneta Tacik; Agnieszka Piwowar
Journal:  Postepy Hig Med Dosw (Online)       Date:  2016-04-18       Impact factor: 0.270

2.  Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer.

Authors:  Josep Martí; Josep Fuster; Anna M Solà; Georgina Hotter; Rafael Molina; Amalia Pelegrina; Joana Ferrer; Ramon Deulofeu; Constantino Fondevila; Juan Carlos García-Valdecasas
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

3.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

Review 4.  Neutrophil gelatinase-associated lipocalin in cancer.

Authors:  Giuseppe Lippi; Tiziana Meschi; Antonio Nouvenne; Camilla Mattiuzzi; Loris Borghi
Journal:  Adv Clin Chem       Date:  2014       Impact factor: 5.394

5.  NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells.

Authors:  Vincenzo Volpe; Zelinda Raia; Luca Sanguigno; Domenico Somma; Paola Mastrovito; Fortunato Moscato; Stefano Mellone; Antonio Leonardi; Francesco Pacifico
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

6.  Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.

Authors:  Min-Che Tung; Shu-Ching Hsieh; Shun-Fa Yang; Chun-Wen Cheng; Rong-Tzong Tsai; Shao-Chuan Wang; Min-Hsien Huang; Yi-Hsien Hsieh
Journal:  Prostate       Date:  2013-06-15       Impact factor: 4.104

7.  Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.

Authors:  J Kellogg Parsons; Michael K Brawer; Carol D Cheli; Alan W Partin; Robert Djavan
Journal:  BJU Int       Date:  2004-07       Impact factor: 5.588

8.  Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer.

Authors:  Frank J G M Kubben; Cornelis F M Sier; Lukas J A C Hawinkels; Harald Tschesche; Wim van Duijn; Kim Zuidwijk; Johan J van der Reijden; Roeland Hanemaaijer; Gerrit Griffioen; Cornelis B H W Lamers; Hein W Verspaget
Journal:  Eur J Cancer       Date:  2007-07-02       Impact factor: 9.162

9.  ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.

Authors:  Navin R Mahadevan; Jeffrey Rodvold; Gonzalo Almanza; Antonio Fernández Pérez; Matthew C Wheeler; Maurizio Zanetti
Journal:  BMC Cancer       Date:  2011-06-07       Impact factor: 4.430

Review 10.  The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases.

Authors:  Vanessa Abella; Morena Scotece; Javier Conde; Rodolfo Gómez; Ana Lois; Jesús Pino; Juan J Gómez-Reino; Francisca Lago; Ali Mobasheri; Oreste Gualillo
Journal:  Biomarkers       Date:  2015-12-15       Impact factor: 2.658

View more
  3 in total

Review 1.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

2.  Bioinformatic analysis of the LCN2-SLC22A17-MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment.

Authors:  Saverio Candido; Barbara Tomasello; Alessandro Lavoro; Luca Falzone; Giuseppe Gattuso; Angela Russo; Sabrina Paratore; James A McCubrey; Massimo Libra
Journal:  Front Cell Dev Biol       Date:  2022-09-21

3.  Lipocalin-2 (LCN2) Deficiency Leads to Cellular Changes in Highly Metastatic Human Prostate Cancer Cell Line PC-3.

Authors:  Sarah K Schröder; Manuela Pinoé-Schmidt; Ralf Weiskirchen
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.